John Crowley (biotech executive)

Last updated
John Crowley
John F. Crowley.jpg
Personal details
Born (1967-04-07) April 7, 1967 (age 56)
Englewood, New Jersey, U.S.
Political party Republican
SpouseAileen Holleran
ChildrenJohn
Megan
Patrick
Alma mater Harvard Business School (MBA)
Notre Dame Law School (JD)
Georgetown University (BS)
United States Naval Academy

John Francis Crowley (born April 7, 1967) is an American biotechnology executive and entrepreneur and the chairman and CEO of Amicus Therapeutics. He co-founded Novazyme Pharmaceuticals with William Canfield, which was later acquired by Genzyme Corporation, [1] and founded Orexigen Therapeutics. In 2006, he was profiled in the book The Cure: How a Father Raised $100 Million – And Bucked the Medical Establishment – In a Quest to Save His Children by Geeta Anand. In 2010, Crowley released his memoir, Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy. [2] Crowley and his family were the inspiration for the movie Extraordinary Measures starring Harrison Ford and Brendan Fraser in 2010. [3] Crowley was named CEO of the Biotechnology Innovation Organization, the largest Biotechnology advocacy organization in the world, in 2023. [4]

Contents

Early life and education

Crowley was raised in Englewood, New Jersey, the son of an Englewood police officer who died in an accident on duty when Crowley was eight years old. [5] [6] His family has Irish and Italian Catholic roots. [7] Crowley's grandfather, John, was a first-generation immigrant from County Cork. [8] His mother worked as a secretary and a waitress. [7]

Crowley attended Bergen Catholic High School in Oradell, New Jersey, graduating with the class of 1985. [9] Crowley attended the United States Naval Academy in Annapolis, Maryland from 1986 to 1987. He went on to earn a B.S. in Foreign Service from Georgetown University. He entered the University of Notre Dame Law School in 1989 and married his wife Aileen in 1990. After receiving his J.D. degree from Notre Dame in 1992, he worked as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham Summers Welsh & Spilman. He went on to receive an M.B.A. degree from Harvard Business School in 1997 and then worked for a management consulting firm in San Francisco. [1] [10]

Career

In 1998, two of Crowley's children, Megan and Patrick, were diagnosed with a severe neuromuscular disorder glycogen storage disease type II, also called Pompe disease. In the face of the children's deteriorating health, the family moved to Princeton, New Jersey to be close to doctors specializing in the disease. [6] [11] Crowley got a job at Bristol-Myers Squibb, immersing himself in health research. He established a foundation to raise money for Pompe awareness [8] and the family worked with non-profit organizations to fund Pompe research. [12] Crowley found that there were researchers in Europe as well as at Duke University, the University of Florida, and University of Oklahoma that were all working on Pompe, but were not communicating. [7] In March 2000, Crowley left Bristol-Myers Squibb and partnered with William Canfield to start Novazyme Pharmaceuticals, a biotechnology research company located in Oklahoma City. Crowley became the company's CEO. [13] [14]

In 2001, Novazyme was acquired by Genzyme Corporation, then the world's third-largest biotechnology company. [1] Crowley, who became senior vice president, was in charge of Genzyme's global Pompe program, the largest R&D effort in the company's history, from September 2001 until December 2002. In January 2003, Megan and Patrick Crowley received the enzyme replacement therapy for Pompe disease developed by Genzyme at St. Peters Hospital in New Brunswick. The therapy, called Lumizyme, is given bi-weekly. [1] [7] The enzyme replacement therapy reduced the size of the children's hearts and improved their muscle strength for a time. [8] The acquisition of Novazyme by Genzyme, and Crowley's fight to cure Pompe's Disease, was documented in the Harvard Business School Case Study, Novazyme: A Father's Love. [15]

Crowley left Genzyme to ensure that his children would qualify for a drug developed by the company. He then became founding president and CEO of Orexigen Therapeutics in 2003. In 2004, he became a director at Amicus Therapeutics, based in Cranbury, New Jersey, and in January 2005, he was named the president and CEO of the company. [16] Amicus works to develop treatments for rare, devastating genetic disorders. The company has a Pompe treatment in development, as well as Galafold (migalastat), which is for Fabry disease. [7] [17] The company's Fabry drug was approved for use in Europe in 2016. [12] [18] The company also has a drug in late stage clinical development for epidermolysis bullosa (EB). [19]

Crowley also served in the United States Navy Reserve as an intelligence officer. He completed a six-month tour of active duty at the Center for Naval Intelligence in Virginia in 2007. [20] He was assigned to a Navy Reserve unit at the United States Special Operations Command.

Crowley is a member of the 2009 class of Henry Crown Fellows at the Aspen Institute. [21]

Politics

In the spring of 2008, Crowley was considered as a potential candidate for the Republican nomination for United States Senate in New Jersey to oppose incumbent Democrat Frank Lautenberg. He did not run due to family and military obligations. [20] Crowley served from 2008 to 2009 as the Honorary Chairman of Building the New Majority, a Continuing Political Committee, the New Jersey state version of a Political Action Committee, that seeks "..to identify, develop and empower local candidates from township committee to the state legislature". [22]

He has been involved in championing numerous public policy causes, most notably in the rare disease and healthcare space. On July 22, 2008, he spoke before several hundred Congressional staffers in the Cannon House Caucus Room on the subject of biotechnology medicines and the protection of patient safety. In July 2010, he testified before the Senate Committee on Health, Education, Labor and Pensions about the state of pediatric rare diseases research. He is widely credited with leading the effort in 2010 to form the bi-partisan Congressional Caucus on Rare Diseases in Washington, DC.

In April 2011, Crowley stepped down from his CEO position at Amicus. At that time, it was speculated that Crowley would run for the Senate as the Republican candidate against Sen. Robert Menendez (D-NJ) in 2012. Crowley did not run for Senate and after completing temporary active duty with the U.S. Navy Reserve, he returned to his position as CEO of Amicus in August 2011. [23] [24] [25]

On June 3, 2013, Senator Frank Lautenberg died, meaning that Governor Chris Christie possessed the ability to appoint a replacement. Crowley was mentioned as a potential replacement, along with Thomas Kean, Tom Kean, Jr., Kim Guadagno, Jon Bramnick, and Joe Kyrillos; [26] ultimately, Christie selected Jeffrey Chiesa for the post.

Philanthropy

Crowley is active in a number of social service and philanthropic efforts. In 2009, he was named to the national board of directors to the Make-A-Wish Foundation of America [27] and became the national chairman of the organization in 2014. [28]

Awards and honors

In 2007, Crowley received the Edward Murphy Award from the University of Notre Dame, given to distinguished lawyers in private practice who have distinguished themselves in the profession of law. [29]

Crowley was awarded an Honorary Doctor of Science from Neumann University in Aston, Pennsylvania where he also delivered the commencement address in 2009. In 2010, he delivered the commencement address at Penn State University, Lehigh Valley. He is a Henry Crown fellow of the Aspen Institute. He has received numerous awards and recognitions for his business leadership and philanthropic efforts, including: New Jersey Biotechnology Industry Organization's 2011 "Dr. Sol J. Barer Award for Vision, Innovation and Leadership"; the 2009 Make A Wish Foundation of New Jersey's "Humanitarian of the Year"; the "2007 E&Y New Jersey Entrepreneur of the Year".

In 2011, Crowley and his wife, Aileen, were given the Family Exemplar Award for their work toward finding treatments for rare diseases by the University of Notre Dame. He received an honorary doctorate degree from the University of Notre Dame and was commencement speaker for the class of 2020 graduation, held in May 2022 as a result of the COVID-19 pandemic. [30]

Books and movie

Crowley was profiled in The Wall Street Journal by Pulitzer Prize-winning journalist Geeta Anand. [31] Anand expanded the profile of Crowley into a book published in 2006, The Cure: How a Father Raised $100 Million – And Bucked the Medical Establishment – In a Quest to Save His Children ( ISBN   978-0060734398). [32]

Harrison Ford and Double Feature films optioned the rights to produce a film inspired by Anand's book and the Crowley family. [33] In April 2009, CBS Films began filming this major motion picture about the Crowley family's quest to save their children's lives. The film, titled Extraordinary Measures [34] [35] was released nationwide on January 22, 2010. Directed by Tom Vaughan, Extraordinary Measures stars Brendan Fraser as John Crowley and Keri Russell as Aileen Crowley, and also executive producer Harrison Ford as "Dr. Robert Stonehill" who is a composite character based primarily on Dr. William Canfield and inspired as well by other doctors Crowley worked with. [36] The film premiered at the University of Notre Dame a week before the official release, [37] [38] and the family attended the red carpet premier in Manhattan. [39] The film was featured at the Re:Image Film Festival held by the Diocese of Trenton in 2010. Crowley attended the event to speak about his family and the film adaptation. [40]

Crowley has also written a personal memoir entitled Chasing Miracles: The Crowley Family Journey of Strength, Hope and Joy, coauthored with Ken Kurson. It was published by New Market Press in January 2010 to coincide with the release of Extraordinary Measures. [41]

Bibliography

Related Research Articles

<span class="mw-page-title-main">Chris John (politician)</span> American politician (born 1960)

Christopher Charles John is an American politician and lobbyist who from 1997 to 2005 served as a Democratic member of the United States House of Representatives for Louisiana's 7th congressional district, since disbanded and merged into the 3rd district.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

<span class="mw-page-title-main">Glycogen storage disease type II</span> Medical condition

Glycogen storage disease type II, also called Pompe disease, and formerly known as GSD-IIa. It is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. GSD-II and Danon disease are the only glycogen storage diseases with a defect in lysosomal metabolism, and Pompe disease was the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.

<span class="mw-page-title-main">Notre Dame Law School</span> Law school of the University of Notre Dame

Notre Dame Law School is the professional graduate law school of the University of Notre Dame. Established in 1869, it is the oldest continuously operating Catholic law school in the United States.

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

<span class="mw-page-title-main">Genzyme</span> Company

Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of Fortune magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America's leading innovators. In February 2022, Sanofi's new corporate brand was unveiled and former entity "Sanofi Genzyme" got integrated into Sanofi.

Sheridan Gray Snyder OBE is an entrepreneur, venture capitalist, and philanthropist in the biotechnology industry. He is the founder and CEO of Biocatalyst, Genzyme and others.

<span class="mw-page-title-main">Michael J. Astrue</span> American lawyer & poet (born 1956)

Michael James Astrue is an American lawyer and, under the pen name A. M. Juster, a poet and critic. He served as Commissioner of the Social Security Administration from 2007 to 2013. Astrue was Poetry Editor of First Things from 2018 to 2020, and became Poetry Editor of Plough Quarterly in 2020.

<span class="mw-page-title-main">Ivor Royston</span> Researcher

Ivor Royston is an American oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.

<span class="mw-page-title-main">National Organization for Rare Disorders</span> U.S. nonprofit organization

The National Organization for Rare Disorders (NORD) is an American non-profit organization aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.

<i>Extraordinary Measures</i> (film) 2010 American film

Extraordinary Measures is a 2010 American medical drama film starring Brendan Fraser, Harrison Ford, and Keri Russell. It was the first film produced by CBS Films, the film division of CBS Corporation, who released the film on January 22, 2010. The film is about parents who form a biotechnology company to develop a drug to save the lives of their children, who have a life-threatening disease. The film is based on the true story of John and Aileen Crowley, whose children have Pompe's disease. The film was shot in St. Paul, Oregon; Portland, Oregon; Tualatin, Oregon; Wilsonville, Oregon; Manzanita, Oregon; Beaverton, Oregon, and Vancouver, Washington.

<span class="mw-page-title-main">Santiago Schnell</span>

Santiago Schnell FRSB FRSC is a scientist and academic leader, currently serving as the William K. Warren Foundation Dean of the College of Science at the University of Notre Dame, as well as a professor in the Department of Biological Sciences, and Department of Applied and Computational Mathematics and Statistics.

William Canfield is a glycobiologist, chief scientific officer and founder of an Oklahoma City-based biotechnology company, Novazyme, which was acquired by Genzyme in August 2001 and developed, among other things, an enzyme that can stabilize Pompe disease, based on Canfield's ongoing research since 1998. Canfield subsequently left Genzyme and established, with his partner in the Novazyme operation, John Crowley, another research laboratory, which he still heads. He saved Cytovance from bankruptcy by forming an investor group and raising $9 million after Crowley suddenly left the lab in 2005 to become the chief executive officer at Amicus Therapeutics in New Jersey

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Amicus Therapeutics</span> Pharmaceutical company

Amicus Therapeutics is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

<span class="mw-page-title-main">Nancy Thornberry</span>

Nancy A. Thornberry is the founding CEO and current chair, R&D at Kallyope Inc. in New York City. She previously worked with Merck Research Laboratories (MRL), joining the company in 1979 as a biochemist and retiring from the position of senior vice president and franchise head, diabetes and endocrinology in 2013.

<span class="mw-page-title-main">ProQR</span> Dutch biotechnology company

ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

References

  1. 1 2 3 4 Crowley, John. "To Save the Children". Notre Dame Lawyer, Spring 2007. Accessed April 4, 2008.
  2. ↑ Kerwick, Mike (January 18, 2010). "Father uses business saavy to fight his kids' rare disease". The Record. Retrieved February 28, 2017.
  3. ↑ Anand, Geeta (December 26, 2014). "One Dad's 14-Year Quest for Cure". The Wall Street Journal. Retrieved February 28, 2017.
  4. ↑ Cohrs, Rachel (2023-12-05). "BIO selects rare disease advocate, biotech executive John Crowley as new CEO". STAT. Retrieved 2023-12-24.
  5. ↑ Secher, Benjamin. "Extraordinary Measures – John Crowley interview", The Daily Telegraph , February 25, 2010. Accessed February 17, 2011.
  6. 1 2 Kerwick, Mike. "Archive: Father uses business savvy to fight his kids' rare disease", The Record (Bergen County) , February 28, 2017. Accessed January 5, 2018. "Crowley has been up for hours. A few miles down the road, at his Princeton home, the 42-year-old CEO of Amicus Therapeutics was helping his teenage daughter.... Their survival is in many ways a tribute to their father, an Englewood native who has spent the last decade raising money to fund research for lifesaving drugs."
  7. 1 2 3 4 5 Michele Alperin (January 20, 2010). "What If Harrison Ford Read About You and Made a Movie?". Princeton Info. Retrieved March 18, 2017.
  8. 1 2 3 Kara Rota (February 2010). "Chasing Miracles: The Crowley Family's Journey". Irish America. Retrieved March 18, 2017.
  9. ↑ Rispoli, Michael. "Republican may make Senate bid, after all", Asbury Park Press , April 4, 2008. Accessed February 17, 2011. "Unanue and Crowley went to high school together at Bergen Catholic in Oradell."
  10. ↑ Amicus Therapeutics, Inc. Executive Profile [ dead link ], BusinessWeek . Accessed April 4, 2008.
  11. ↑ Edelstein, Jeff. "Look Who's Talking: John Crowley, dad, entrepreneur, and subject of the upcoming film Extraordinary Measures" Archived 2012-03-14 at the Wayback Machine , The Trentonian , January 11, 2010. Accessed February 17, 2011. "Princeton's Crowley family, from left, Megan, Aileen, John, Patrick, and John Jr. John Crowley, a Princeton Township resident, is the father of two children with Pompe disease."
  12. 1 2 Jessica Milvihill Moran (August 28, 2016). "A father's mission: How one man developed a drug to save the lives of his children". Fox News. Retrieved March 18, 2017.
  13. ↑ "John Crowley On The Today Show 2001". Youtube.com, September, 2001. Accessed June 16, 2008.
  14. ↑ Benjamin Secher (February 25, 2010). "Extraordinary Measures - John Crowley interview". Telegraph. Retrieved March 18, 2017.
  15. ↑ "A Father's Love: Novazyme Pharmaceuticals, Inc. ". Harvard.edu, October, 2002. Accessed June 14, 2011.
  16. ↑ Senior Management Team Archived 2008-03-02 at the Wayback Machine , Amicus Therapeutics. Accessed April 4, 2008.
  17. ↑ Selina McKee (January 4, 2017). "NICE backs Amicus' Galafold for Fabry disease". Pharmatimes. Retrieved March 18, 2017.
  18. ↑ Abigail Stevenson (January 21, 2015). "A life-saving biotech with a personal mission". CNBC. Retrieved March 18, 2017.
  19. ↑ "Amicus Is A Winner". Seeking Alpha. September 23, 2016. Retrieved March 18, 2017.
  20. 1 2 "Crusading dad John Crowley may run for U.S. Senate". The Star-Ledger , March 28, 2008. Accessed April 4, 2008.
  21. ↑ "2009 Class of Henry Crown Fellows", The Aspen Institute. Accessed September 12, 2011.
  22. ↑ "Building the New Majority website Archived 2008-06-22 at archive.today . Accessed June 28, 2008.
  23. ↑ Cooper, Kent (2011-04-19). "John Crowley Potentially Eyeing New Jersey Senate Bid Vs. Menendez : Roll Call Politics". Rollcall.com. Retrieved 2013-04-12.
  24. ↑ Scott Morgan (July 6, 2011). "Senate Out, Amicus Back In for Crowley". U.S. 1. Retrieved March 18, 2017.
  25. ↑ "Republican hopeful John Crowley announces he will not seek U.S. Senate bid". NJ.com. June 29, 2011. Retrieved March 18, 2017.
  26. ↑ Trygstad, Kyle (June 3, 2013). "Christie Holds Keys to Lautenberg Succession". Roll Call . Retrieved June 4, 2013.
  27. ↑ Aragon, Mabel (December 9, 2009). "John F. Crowley Joins Make-A-Wish Foundation of America Board of Directors". NJ.com. Retrieved March 18, 2017.
  28. ↑ "March of Dimes Honors John F. Crowley". Princeton Patch. June 5, 2014. Retrieved March 18, 2017.
  29. ↑ "Awards". University of Notre Dame. Retrieved March 18, 2017.
  30. ↑ "2011 Recipients". University of Notre Dame. Retrieved March 18, 2017.
  31. ↑ Anand, Geeta. "For His Sick Kids, a Father Struggled to Develop a Cure". The Wall Street Journal , August 26, 2003. Accessed April 4, 2008.
  32. ↑ "Taking Matters Into His Own Hands". Notre Dame Magazine, Spring 2007. Accessed November 28, 2011.
  33. ↑ "Crowley Lures Harrison Ford To CBS". Variety.com, June 9, 2008. Accessed June 16, 2008.
  34. ↑ "Extraordinary Measures". IMDb. Archived from the original on 2010-01-27. Retrieved 2009-09-29.
  35. ↑ "News and Culture: Brenden Fraser's Untitled Crowley Project Now Has (Another) Terrible Title". Willamette Week . September 24, 2009. Archived from the original on August 26, 2009. Retrieved 2009-09-29.
  36. ↑ "The Successful Effort to Develop Myozyme for Pompe Disease at Genzyme FAQs" Archived January 25, 2010, at the Wayback Machine
  37. ↑ Ferraro, Caitlin. "Determined Dad Defies Odds in "Extraordinary Measures"".
  38. ↑ Metz, Jenn. "A father's quest".
  39. ↑ Ridley, Jane. "The Crowley family, portrayed in 'Extraordinary Measures,' fought to find cure for Pompe disease". New York Daily News .
  40. ↑ Alessi, Scott. "Inspired By A True Story".
  41. ↑ "An 'Extraordinary' welcome – Fans crowd aisles for 'Chasing Miracles' author". The Times (Trenton). 2010-01-24. Retrieved 2010-01-25.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.